Neural Stem Cells New Therapy for Neuroinflammation

Neural Stem Cells and Progenitor Cells as a Multimodal Strategy for Controlling Neuroinflammation Neuroinflammation is no longer regarded as a secondary phen…

Neural Stem Cells and Progenitor Cells as a Multimodal Strategy for Controlling Neuroinflammation

Neuroinflammation is no longer regarded as a secondary phenomenon accompanying neurological disease. It is increasingly understood as a dynamic biological process that can determine whether the central nervous system (CNS) progresses toward tissue destruction or enters a state compatible with repair. Persistent activation of microglia and astrocytes, disruption of the blood–brain barrier (BBB), infiltration of peripheral immune cells, oxidative stress, mitochondrial dysfunction, excitotoxicity, impaired oligodendrocyte function, and failure of endogenous regeneration form interconnected pathological networks rather than isolated abnormalities. This complexity helps explain why conventional anti-inflammatory treatments can reduce inflammatory activity without necessarily restoring neural tissue or reversing established neurological disability.

Neural stem and progenitor cells (NSPCs) are particularly interesting because their potential extends beyond simple cellular replacement. NSPCs can differentiate toward neuronal, astroglial, and oligodendroglial lineages, but a substantial component of their therapeutic activity appears to arise from paracrine and immunomodulatory mechanisms. Transplanted NSPCs can interact with microglia, astrocytes, infiltrating immune cells, endothelial cells, oligodendrocyte-lineage cells, and endogenous neural progenitors. Through this cellular dialogue, they may suppress excessive inflammatory signaling, promote a more reparative immune phenotype, support neuronal survival, stimulate remyelination, preserve BBB integrity, and alter the local tissue environment.

An additional dimension is provided by extracellular vesicles (EVs), including exosome-enriched populations, released by neural progenitor cells and other therapeutic stem-cell populations. These vesicles transport microRNAs (miRNAs), proteins, lipids, and other regulatory molecules capable of modifying gene expression in recipient cells. Thus, cell therapy can be conceptualized not merely as transplantation of a population of replacement cells, but as delivery of a dynamic biological system capable of sensing and responding to the diseased microenvironment.

This review examines the biological causes and major forms of neuroinflammation, explains why conventional approaches may be insufficient in chronic CNS disease, and focuses specifically on neural stem/progenitor cells, their differentiation, paracrine signaling, extracellular vesicles, and miRNA-mediated regulation. Intravenous, intrathecal, and intranasal delivery strategies are compared from a translational perspective. Particular attention is given to the distinction between experimental mechanisms and clinically established efficacy. The emerging therapeutic model is that successful neuroregeneration may require simultaneous control of pathological inflammation, restoration of cellular homeostasis, remyelination, neuroprotection, and reconstruction of the regenerative microenvironment. About success rate of stem cells therapy

Introduction: Why Neuroinflammation Is More Than “Brain Inflammation”

Neuroinflammation is often described in simple terms as inflammation occurring within the nervous system. This definition is technically correct but biologically incomplete. The CNS possesses a highly specialized immune environment in which resident microglia, astrocytes, neurons, endothelial cells, oligodendrocytes, perivascular cells, and infiltrating immune populations communicate continuously. Under physiological conditions, this communication supports tissue surveillance, synaptic remodeling, removal of cellular debris, metabolic homeostasis, and responses to injury.

The problem begins when an initially protective response becomes persistent, disproportionate, or spatially misdirected.

After an acute injury, inflammation can be beneficial. Damaged cells must be recognized, debris must be removed, and regenerative pathways must be activated. Microglia are therefore not inherently “bad” cells. They can participate in tissue protection, phagocytosis, trophic support, and repair. Likewise, astrocytes can contribute to metabolic support and restoration of the extracellular environment. Modern neuroimmunology therefore increasingly distinguishes between protective or resolving inflammation and chronic maladaptive neuroinflammation.

The pathological situation arises when inflammatory signaling becomes self-sustaining.

A useful conceptual model is a positive feedback loop:

initial injury → danger signals → microglial/astrocytic activation → inflammatory mediators → neuronal and oligodendrocyte stress → additional cellular damage → additional danger signals → further glial activation.

In this model, the inflammatory response eventually becomes partially independent of the original trigger.

This is one reason why simply suppressing one inflammatory mediator may not be sufficient. The pathological system has several interconnected nodes. Cytokines influence microglia; microglia influence astrocytes; astrocytes affect neurons and oligodendrocytes; damaged myelin generates additional danger-associated signals; mitochondrial dysfunction increases oxidative stress; BBB disruption allows additional immune-cell traffic; and neuronal injury itself can perpetuate inflammatory signaling.

Consequently, chronic neuroinflammation is better understood as a network disorder of the CNS microenvironment than as a single molecular pathway.

This concept is particularly important for regenerative medicine.

A neuron transplanted into a chronically inflammatory environment may encounter oxidative stress, abnormal extracellular glutamate, altered trophic signaling, dysfunctional glia, impaired vascular support, and inadequate myelination. Even if the transplanted cell survives, the environment may prevent meaningful functional integration.

Therefore, an ideal regenerative therapy should not only provide cells. It should help change the environment in which those cells—and the patient's own remaining neural cells—must function.

This is one of the reasons neural stem and progenitor cells have attracted attention.

Major Causes and Clinical Contexts of Neuroinflammation

Neuroinflammation occurs in numerous neurological conditions, although the initiating mechanisms differ.

Autoimmune and demyelinating disease

Multiple sclerosis (MS) provides one of the clearest examples of the relationship between inflammation, demyelination, axonal injury, and neurodegeneration. In relapsing disease, peripheral immune mechanisms contribute substantially to inflammatory lesion formation. However, as disease becomes progressive, CNS-compartmentalized inflammation, microglial activation, mitochondrial dysfunction, axonal loss, and failure of remyelination become increasingly important.

This distinction is critical.

A treatment can be highly effective at reducing new inflammatory lesions and still have limited ability to reverse established neurological disability. The biological reason is straightforward: suppressing the formation of new inflammatory lesions does not automatically replace neurons that have already died, restore damaged axons, rebuild myelin, or normalize a chronically activated CNS microenvironment.

This creates an important therapeutic gap.

Neurodegenerative disease

Neuroinflammation is also associated with Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and other neurodegenerative disorders.

In these conditions, inflammation may be linked to protein aggregation, mitochondrial dysfunction, impaired autophagy, synaptic abnormalities, neuronal death, oxidative stress, and changes in microglial phenotype.

The relationship is bidirectional.

Neuronal dysfunction activates glial cells, while chronically activated glia can release inflammatory and oxidative mediators that further stress neurons.

Thus:

neurodegeneration → glial activation → inflammatory signaling → additional neuronal stress → further neurodegeneration.

Breaking this cycle requires more than simply eliminating one inflammatory molecule.

Stroke and ischemic injury

After ischemic stroke, neuroinflammation develops in response to tissue damage and cell death. Microglia and infiltrating immune cells recognize injury-associated molecular patterns. Astrocytes become reactive, BBB permeability changes, and inflammatory mediators accumulate.

Some inflammatory mechanisms contribute to secondary injury, whereas others participate in debris clearance and tissue repair.

This duality illustrates why indiscriminate immune suppression can theoretically interfere with beneficial repair processes.

Traumatic CNS injury

Traumatic brain and spinal cord injury demonstrate another important principle.

The initial mechanical injury may be irreversible, but secondary injury can continue for days, weeks, or longer. Glial activation, oxidative stress, excitotoxicity, vascular dysfunction, and inhibitory extracellular signals can create a hostile environment around surviving neurons and axons.

NSCs and progenitor cells are therefore being investigated not only for their ability to generate neural cells but also for their ability to alter this secondary environment. Experimental studies of spinal cord injury have described immunomodulation, trophic support, neuronal/glial differentiation, and potential effects on myelination as complementary mechanisms.

Infection and post-infectious inflammation

Viral and other infectious processes can activate CNS innate immune pathways. Even when the infectious trigger is controlled, inflammatory signaling may persist.

The therapeutic challenge becomes particularly difficult because excessive immunosuppression during active infection may be harmful.

This highlights an important principle for stem-cell research: regenerative immunomodulation must be understood as context dependent, not simply equivalent to “more anti-inflammatory activity.”

Why Standard Anti-Inflammatory Treatment May Be Insufficient

It is important to emphasize that conventional treatments can be highly valuable. In MS, for example, disease-modifying therapies can substantially reduce relapse activity and new inflammatory lesions. Their limitation is not that they “do nothing,” but that many were designed primarily to control particular immune mechanisms rather than reconstruct damaged CNS tissue.

This distinction explains much of the interest in regenerative approaches.

- Inflammation is not the only problem

Once chronic CNS disease becomes established, pathology may include:

persistent microglial activation;

reactive astrogliosis;

axonal degeneration;

neuronal loss;

oligodendrocyte dysfunction;

failed remyelination;

mitochondrial impairment;

oxidative stress;

altered synaptic signaling;

BBB dysfunction;

extracellular matrix remodeling;

impaired endogenous progenitor activity.

A therapy aimed at only one of these components may leave the others untouched.

- Peripheral immune suppression does not necessarily normalize the CNS microenvironment

Some disease-modifying therapies primarily influence immune cells outside the CNS. This can be very effective in reducing new inflammatory events, but progressive disease may increasingly involve mechanisms occurring inside the CNS itself.

Recent reviews of progressive MS emphasize persistent CNS-compartmentalized inflammation and neurodegeneration as important contributors to disability, helping explain why conventional immunomodulation may have limited effects during progressive stages.

- Suppression is not the same as resolution

An important distinction is:

anti-inflammatory therapy: reduces inflammatory signaling.

pro-resolving therapy: actively encourages restoration of tissue homeostasis.

regenerative therapy: additionally supports replacement, repair, remyelination, or reconstruction.

An ideal future treatment may combine all three concepts.

This is where NSPCs become conceptually different from many conventional pharmacological approaches.

Neural Stem Cells and Neural Progenitor Cells: What Are They?

Neural stem cells (NSCs) are cells capable of self-renewal and differentiation toward multiple neural lineages. Neural progenitor cells (NPCs) are more developmentally restricted descendants with substantial proliferative capacity but narrower differentiation potential.

Together they are frequently discussed as neural stem/progenitor cells (NSPCs).

Their major potential lineages include:

NSPC → neurons

NSPC → astrocytes

NSPC → oligodendrocyte-lineage cells

The biological significance of this differentiation capacity is obvious: the nervous system requires several cell types to maintain functional circuitry.

But an important modern insight is that differentiation is probably only part of the therapeutic mechanism.

Early regenerative medicine frequently imagined a relatively simple sequence:

transplant cells → cells become neurons → new neurons replace dead neurons → function improves.

The biology appears to be considerably more complex.

Many experimental observations indicate that transplanted NSPCs exert substantial effects through paracrine signaling and immunomodulation, even when only a relatively small fraction of administered cells ultimately become mature neurons. Recent reviews emphasize that NSPC-mediated regulation of neuroinflammation is strongly associated with secreted factors and interaction with microglia and astrocytes.

This changes the conceptual definition of cell therapy.

NSPCs should not necessarily be viewed as passive “replacement bricks.”

They can behave more like biological regulators of the injured microenvironment.

The Unique Therapeutic Concept: Cells That Respond to the Environment

One of the most interesting properties of stem/progenitor-cell therapies is biological plasticity.

A pharmaceutical molecule generally has a relatively defined pharmacological target. A transplanted cell is different. It can encounter inflammatory cytokines, hypoxia, oxidative stress, extracellular matrix signals, growth factors, immune cells, and damaged tissue.

Those signals can change cellular behavior.

The therapeutic cell can therefore function as a responsive biological system.

This is particularly important in neuroinflammation because the pathological environment is heterogeneous.

One lesion may be dominated by activated microglia.

Another may contain substantial demyelination.

A third may have neuronal loss and mitochondrial dysfunction.

A fourth may have severe BBB disruption.

A single static molecular intervention may not be optimal for all four environments.

NSPCs potentially respond to these different microenvironments by changing their secretome.

This property is sometimes described as therapeutic plasticity.

The concept does not mean that stem cells magically “know” where disease is located. Rather, their behavior is influenced by molecular signals within damaged tissues, and some experimental studies demonstrate migration toward injury-associated environments and changes in secretory behavior

NSPCs and Microglia: One of the Central Mechanisms

Microglia are resident immune cells of the CNS and major regulators of neuroinflammatory responses.

They can adopt different functional states depending on environmental conditions.

Simplified terminology often divides them into “pro-inflammatory M1” and “anti-inflammatory M2” states. However, modern single-cell studies demonstrate that microglial biology is substantially more continuous and complex than this binary classification.

The important question is therefore not simply:

“Can stem cells turn M1 into M2?”

A more accurate question is:

“Can NSPCs shift microglial behavior from a chronically damaging inflammatory state toward a state more compatible with debris clearance, trophic support, resolution, and tissue repair?”

Evidence summarized in recent reviews suggests that NSPCs can influence microglial survival, proliferation, migration, phagocytosis, and activation through direct cellular interactions and secreted mediators.

Potential consequences include reduction of inflammatory cytokine signaling and enhancement of reparative processes.

The importance of this mechanism becomes clearer when considering the inflammatory feedback loop.

Activated microglia release mediators that can activate astrocytes.

Reactive astrocytes can produce signals that affect neurons and oligodendrocytes.

Damaged neurons release danger-associated signals.

These signals further activate microglia.

NSPCs may interrupt this cycle at several points.

NSPCs and Astrocytes: Reprogramming the Tissue Environment

Astrocytes are essential for CNS homeostasis. They regulate extracellular ions, neurotransmitters, metabolic support, BBB function, synaptic physiology, and interactions with neurons.

However, after CNS injury, astrocytes can become reactive.

Reactive astrogliosis is not necessarily harmful in itself. It can help isolate damaged tissue and contribute to repair. But prolonged or excessive reactive states can become associated with inhibitory extracellular environments and persistent inflammatory signaling.

NSPC-derived signals may influence astrocytic behavior.

The therapeutic objective is not to eliminate astrocytes or completely suppress astrogliosis.

Instead, the goal is to encourage a transition from a persistently damaging inflammatory state toward a phenotype that supports homeostasis and regeneration.

Recent reviews describe NSPC-mediated modulation of both microglial and astrocytic activation, potentially disrupting the positive-feedback relationship between these glial populations.

This is one reason NSPC therapy may be conceptually different from a conventional anti-inflammatory drug.

The target is not merely a cytokine.

The target is the cellular ecosystem.

Differentiation: Why Neurons Are Only One Part of the Story

NSPC differentiation is central to regenerative neuroscience.

Neuronal differentiation

Differentiation into neurons could theoretically contribute to replacement of cells lost during disease or injury.

However, functional neuronal replacement is exceptionally demanding.

A new neuron must:

survive;

differentiate appropriately;

migrate or remain in the correct anatomical region;

establish synaptic connections;

receive appropriate inputs;

generate appropriate outputs;

integrate with existing circuitry;

maintain long-term physiological stability.

Therefore, “NSCs become neurons” should not be interpreted as equivalent to “the brain has been repaired.”

The functional integration problem is one of the major challenges in regenerative neuroscience.

Oligodendrocyte differentiation and remyelination

The oligodendrocyte lineage is particularly important in demyelinating disease.

Axons depend on myelin for efficient electrical conduction. Loss of myelin can produce conduction abnormalities and expose ns to additional metabolic stress.

NSPC-derived oligodendrocyte-lineage cells may potentially contribute to remyelination.

But again, endogenous repair mechanisms also exist.

The therapeutic objective may therefore be twofold:

direct contribution to new oligodendroglial cells + stimulation of the patient's own remyelinating capacity.

This combined mechanism may be more biologically plausible than assuming that transplanted cells alone will rebuild all damaged myelin.

Astrocytic differentiation

Astrocytes derived from progenitor populations may provide metabolic and trophic support.

However, differentiation must be controlled carefully because astrocytes can be beneficial or maladaptive depending on their state and location.

This is one reason modern research increasingly focuses on cell state and secretome, rather than merely lineage percentages.

Paracrine Signaling: The Hidden Half of Cell Therapy

The paracrine effect refers to biological communication in which cells release molecules that influence neighboring or distant cells.

For NSPCs, potentially relevant factors include:

neurotrophic factors;

immunoregulatory cytokines;

growth factors;

extracellular vesicles;

miRNAs;

proteins;

lipids;

metabolic signals.

Recent reviews identify increased production of regulatory mediators such as IL-10 and TGF-β, alongside trophic factors including BDNF, GDNF, and IGF-1, as part of the proposed NSPC-mediated regenerative environment.

These factors can influence several processes simultaneously.

For example:

microglia modulation → reduced inflammatory stress → improved neuronal survival

while:

trophic signaling → enhanced endogenous progenitor activity → improved repair

and:

oligodendroglial support → improved remyelination → improved axonal function.

The therapeutic effect therefore becomes multidimensional.

Extracellular Vesicles: A Cell-Free Extension of Stem Cell Biology

Extracellular vesicles (EVs) are membrane-bound particles released by cells.

They include several populations, among which exosomes are one well-known subgroup.

EVs can contain:

proteins;

lipids;

messenger RNAs;

microRNAs;

other non-coding RNAs;

signaling molecules;

metabolites.

Their importance is that they can transport biologically active information from one cell to another.

This creates an intriguing possibility:

Perhaps part of what makes stem cells therapeutically useful can be delivered without permanently transplanting the cells themselves.

Neural stem/progenitor-cell-derived EVs have attracted particular interest because they may retain neuroprotective, neuroregenerative, and immunomodulatory properties of their parent cells while potentially reducing some challenges associated with living-cell transplantation.

This does not mean that EV therapy has already replaced cellular therapy.

It has not.

Manufacturing, purification, characterization, biodistribution, potency testing, dosing, and long-term safety remain major translational questions. Recent literature specifically identifies heterogeneity of EV isolation methods, scalability, and insufficient long-term biodistribution data as obstacles to clinical translation.

microRNAs: Small Molecules With Large Regulatory Potential

MicroRNAs are short non-coding RNAs that regulate gene expression post-transcriptionally.

Their importance comes from their ability to influence networks of genes rather than a single protein.

This is particularly attractive for neuroinflammation because pathological inflammation is itself a network phenomenon.

Instead of inhibiting one cytokine, a miRNA can potentially regulate multiple components of a signaling pathway.

Important inflammatory pathways under investigation include:

NF-κB signaling;

Toll-like receptor pathways;

inflammasome-associated signaling;

oxidative-stress pathways;

apoptosis;

microglial activation;

mitochondrial function.

One frequently investigated example is miR-146a, which is associated with negative regulation of inflammatory signaling and has been studied in extracellular-vesicle-mediated immunomodulation. Experimental work has demonstrated MSC-EV effects involving the miR-146a/NF-κB axis.

However, it is essential not to oversimplify this mechanism.

A single miRNA is unlikely to be a universal treatment for neuroinflammation.

The therapeutic effect of an EV may result from a combination of miRNAs, proteins, lipids, and other cargoes acting together.

This is another reason EVs are biologically interesting.

They resemble a naturally occurring communication package rather than a single drug molecule.

Why Neural EVs May Be Particularly Interesting

EVs produced by different cell types are not biologically identical.

An EV released by a neural progenitor cell may carry information reflecting the biology of neural tissue.

This raises the possibility that neural-cell-derived EVs could have advantages for CNS applications.

NSC-derived EVs have been investigated for their potential to cross biological barriers, modulate inflammatory environments, protect neurons, and promote regeneration.

The attraction is therefore not simply that EVs are small.

Their potential advantage is that they represent biological information encoded in a transferable package.

A future therapeutic platform could potentially combine:

NSPC transplantation

with

NSPC-derived EVs

with

engineered or enriched regulatory RNA cargo

with

neurotrophic support

and

remyelination-oriented interventions.

Such a strategy would be substantially different from conventional anti-inflammatory pharmacology.

Blood–Brain Barrier: The Fundamental Delivery Problem

The BBB is one of the greatest challenges in neurological medicine.Stem cell therapy for diseases of nervous system

It protects the brain from many circulating substances but simultaneously makes it difficult to deliver therapeutic molecules and cells into CNS tissue.

This creates a paradox:

the brain needs treatment, but the biological system designed to protect the brain limits access to treatment.

This is one reason route of administration becomes important in stem-cell research.

Three major approaches frequently discussed are:

intravenous administration;

intrathecal administration;

intranasal administration.

Each has a different biological logic.

Intravenous Administration

Intravenous administration is attractive because it is relatively familiar, scalable, and minimally invasive compared with direct CNS transplantation.

The theoretical model is:

systemic administration → circulation → interaction with immune/vascular compartments → migration or signaling toward injured tissue.

However, intravenous administration does not mean that all administered cells reach the brain.

A significant proportion of cells may initially distribute to organs such as the lungs, liver, spleen, and other vascular beds. This is one of the major limitations of systemic cell delivery.

Nevertheless, this apparent limitation may not completely eliminate therapeutic potential.

If part of the therapeutic effect is mediated by systemic immunomodulation or secreted factors, direct physical accumulation of every cell in the CNS may not be necessary.

This creates two possible mechanisms:

direct CNS homing

and

indirect systemic immunomodulation followed by CNS effects.

The relative contribution of each mechanism remains an important research question.

Intrathecal Administration

Intrathecal delivery introduces the therapeutic product into the cerebrospinal-fluid compartment.

The theoretical advantage is proximity to the CNS.

Compared with intravenous administration, the therapeutic product does not have to cross the systemic vascular barrier in the same way.

This may increase exposure to the CNS environment.

The trade-off is invasiveness.

Intrathecal administration requires a procedure involving the cerebrospinal-fluid compartment and therefore cannot be considered equivalent to an ordinary intravenous infusion.

Clinical research has investigated intrathecal delivery of stem-cell-derived products, including MSC-based therapies, with systematic reviews suggesting generally acceptable safety profiles in selected trials but emphasizing the need for larger, better-designed studies.

Importantly, evidence for MSCs cannot automatically be transferred to NSPCs.

Different cell populations have different biological properties, manufacturing requirements, risks, and pharmacology.

Therefore:

“stem cells are safe intrathecally” is not a sufficiently precise scientific statement.

Safety must be evaluated for the specific product, cell type, manufacturing process, route, and patient population.

Intranasal Administration

Intranasal delivery is particularly attractive because the nasal cavity provides anatomical pathways that can partially circumvent the BBB.

Olfactory and trigeminal pathways, along with perivascular routes, have been investigated as potential mechanisms allowing therapeutic material to reach the CNS.

The theoretical advantages include:

non-invasive or minimally invasive administration;

avoidance of systemic first-pass distribution;

potential direct CNS access;

repeated administration as a future possibility;

reduced need for invasive CNS procedures.

Experimental studies have reported CNS migration and functional effects after intranasal stem-cell administration.

However, translational evidence remains limited.

A 2026 systematic review of human clinical studies identified only a small number of participants and substantial heterogeneity between studies, products, neurological conditions, and administration routes. The authors concluded that intranasal stem-cell administration appears feasible and potentially safe but that high-quality randomized studies are still required.

Therefore, intranasal therapy should currently be described as promising and investigational, rather than established treatment.

Comparing the Three Routes Conceptually

Route	Main theoretical advantage	Main limitation
Intravenous	Simple systemic delivery and potential immunomodulation	Limited direct CNS biodistribution
Intrathecal	Greater proximity to CNS/CSF compartment	Invasive procedure and procedure-related risks
Intranasal	Potential BBB bypass and direct CNS access	Variable delivery efficiency and limited clinical evidence

The important conclusion is that there is no universally superior route.

The correct route depends on:

the therapeutic product;

target disease;

anatomical distribution of pathology;

desired mechanism;

cell survival requirements;

biodistribution;

safety profile;

clinical-trial design.

A future therapeutic platform may even use different routes for different biological objectives.

A More Complete Model: “Inflammation → Repair → Regeneration”

The most promising conceptual shift is to stop thinking of stem-cell therapy as a single mechanism.

Instead, imagine four overlapping stages.

Stage 1: Immune stabilization

NSPCs and their secreted factors interact with microglia, astrocytes, peripheral immune cells, and inflammatory pathways.

The goal is not complete immune suppression.

The goal is to reduce destructive inflammation while preserving protective immune functions.

Stage 2: Neuroprotection

As inflammatory and oxidative stress decreases, vulnerable neurons and oligodendrocytes may become more resistant to further injury.

Trophic factors can additionally support cellular survival.

Stage 3: Regeneration

NSPCs can potentially differentiate into neural lineages and stimulate endogenous progenitor activity.

Stage 4: Functional reconstruction

Successful repair ultimately requires:

axonal integrity;

synaptic organization;

remyelination;

vascular support;

metabolic normalization;

restoration of neural networks.

This is the fundamental reason that cell therapy is potentially more than an anti-inflammatory therapy.

It attempts to alter the trajectory from:

chronic inflammation → degeneration

toward:

controlled inflammation → protection → repair → regeneration.

The Role of Mitochondria and Oxidative Stress

Neuroinflammation cannot be separated from cellular metabolism.

Neurons have exceptionally high energetic requirements. Axonal transport, membrane potential maintenance, synaptic transmission, and ion gradients all depend heavily on mitochondrial function.

Chronic inflammation can increase oxidative stress and impair mitochondrial efficiency. Mitochondrial Dysfunction: The Hidden Driver Behind Chronic Disease and Healthy Aging

Mitochondrial dysfunction can then produce additional danger signals and worsen inflammatory activation.

This creates another feedback loop:

inflammation → mitochondrial stress → oxidative stress → neuronal dysfunction → danger signaling → inflammation.

NSPC-derived paracrine signaling and EVs are being investigated for their ability to influence cellular metabolism and mitochondrial homeostasis.

Recent work on NSC-derived EVs specifically highlights neuroinflammation, neuroregeneration, restoration of cellular bioenergetics, and even potential mitochondrial transfer as areas of interest.

This suggests that the therapeutic role of stem cells may extend beyond immunology into cellular bioenergetics.

Neuroinflammation and Remyelination

Remyelination is a major regenerative challenge.

In a healthy CNS, oligodendrocyte precursor cells can respond to demyelination and generate new myelin-producing oligodendrocytes.

In chronic disease, however, this repair system can become inefficient.

Possible reasons include:

persistent inflammation;

inhibitory extracellular matrix;

aging of progenitor populations;

altered growth-factor signaling;

metabolic stress;

axonal degeneration;

failure of progenitor recruitment or differentiation.

NSPC therapy could theoretically contribute at several levels:

direct oligodendroglial differentiation;

trophic support for endogenous progenitors;

modulation of microglial activity;

reduction of inflammatory inhibition;

support of axonal survival.

Therefore, the therapeutic target is not simply “more oligodendrocytes.”

It is the entire remyelination environment.

Why the Microenvironment Matters More Than Cell Number

A common misconception in regenerative medicine is that more cells necessarily produce greater regeneration.

Biologically, this is not guaranteed.

Cell survival depends on the environment.

If the recipient tissue contains high inflammatory signaling, oxidative stress, poor vascular support, or toxic extracellular factors, increasing the number of transplanted cells may not solve the underlying problem.

This leads to an important research principle:

cell quality + cell state + microenvironment + delivery route may matter more than cell number alone.

For this reason, modern cell-therapy research increasingly investigates preconditioning, differentiation state, secretome composition, EV cargo, tissue compatibility, and biomarkers of therapeutic potency.

Neural Progenitors Versus Mesenchymal Stem Cells

Mesenchymal stem/stromal cells (MSCs) have generated substantial interest because of their immunomodulatory secretome and relatively accessible tissue sources.

NSPCs are conceptually different.

MSCs are not primarily neural cells.

Their major proposed therapeutic effects are often paracrine and immunomodulatory.

NSPCs, by contrast, possess neural-lineage potential in addition to immunomodulatory activity.

This creates a potentially broader mechanism:

MSCs → immunomodulation + trophic support + EV-mediated signaling

versus

NSPCs → immunomodulation + trophic support + EV signaling + neural-lineage differentiation + potential remyelination.

This comparison should not be interpreted as evidence that NSPCs are clinically superior.

Direct comparative clinical evidence remains insufficient.

Instead, it illustrates why NSPCs are scientifically attractive for CNS repair.

The Importance of Extracellular Vesicles as an Adjunct Rather Than a Replacement

An emerging strategy is to consider EVs as complementary to living-cell therapy.

One possible model is:

NSPCs provide a dynamic biological source of repair signals.

NSPC-derived EVs provide a concentrated, cell-free form of selected signaling information.

This could eventually allow researchers to separate different components of the therapeutic effect.

For example:

living cells for prolonged environmental sensing;

EVs for targeted molecular communication;

defined miRNA cargo for pathway regulation;

trophic factors for neuroprotection.

However, this remains a research framework rather than an established clinical protocol.

Why EVs and miRNAs Are Particularly Attractive for Neuroinflammation

Neuroinflammation is characterized by multiple simultaneous molecular abnormalities.

For example:

TLR activation

can stimulate:

NF-κB signaling

which promotes:

inflammatory cytokine production

which can contribute to:

microglial activation

which contributes to:

neuronal and oligodendrocyte stress.

A single drug targeting one component may not normalize the entire network.

miRNAs can potentially influence multiple nodes simultaneously.

EVs can deliver combinations of miRNAs and proteins.

This is biologically closer to the way cells naturally communicate.

In other words:

traditional pharmacology often attempts to control one pathway; EV biology may allow modulation of a network.

That is one of the most compelling scientific arguments for EV-based regenerative medicine.

Biomarkers: How Will We Know Whether Neuroinflammation Is Actually Improving?

A major challenge in clinical translation is determining whether a therapy is genuinely changing disease biology.

Symptoms alone are insufficient.

Future trials may require combinations of:

MRI markers;

cerebrospinal-fluid biomarkers;

blood-based inflammatory markers;

neurofilament measurements;

imaging of microglial activation;

electrophysiological measures;

cognitive assessments;

motor-function testing;

biomarkers of remyelination;

longitudinal disability measurements.

The goal should be to distinguish:

temporary symptomatic improvement

from:

biological modification of disease.

For stem-cell therapies, this distinction is particularly important because placebo effects and rehabilitation-related improvement can complicate interpretation.

The Difference Between Anti-Inflammation and Disease Modificat

A successful therapy should ideally answer three questions.

Question 1: Did inflammation decrease?

This can be evaluated using inflammatory biomarkers and imaging.

Question 2: Did tissue become healthier?

This requires evidence of neuroprotection, reduced axonal injury, improved myelin integrity, or other biological changes.

Question 3: Did neurological function improve or stabilize?

This requires validated clinical outcomes.

Only when these levels converge can researchers confidently claim meaningful disease modification.

This is particularly important for progressive neurological disease, where slowing disability accumulation may be as important as producing measurable improvementsNeuroinflammation is a complex, dynamic process that connects immune activation with neuronal injury, demyelination, oxidative stress, mitochondrial dysfunction, BBB disruption, and failure of regeneration. Conventional anti-inflammatory therapies remain essential for many neurological diseases, but their ability to restore already damaged CNS tissue is limited. This limitation is particularly evident in progressive neurodegenerative and demyelinating conditions, in which pathology increasingly becomes compartmentalized within the CNS and involves mechanisms beyond peripheral immune activation.

Neural stem and progenitor cells provide a fundamentally different therapeutic concept.

Their potential is not restricted to differentiation into neurons.

NSPCs can potentially influence the CNS microenvironment through paracrine signaling, regulate microglial and astrocytic states, support neuronal survival, stimulate endogenous repair, contribute to oligodendroglial regeneration, and participate in remyelination. Recent evidence emphasizes that many of these effects may occur through secreted factors rather than direct cellular replacement alone.

Extracellular vesicles expand this concept further.

NSPC-derived EVs can carry proteins, lipids, and regulatory RNAs, including microRNAs capable of influencing inflammatory and regenerative pathways. Their potential to deliver complex biological information makes them an especially interesting bridge between cellular therapy and molecular therapy.

The role of miRNAs is particularly significant because they can regulate gene networks rather than individual inflammatory molecules. miRNA-containing EVs may therefore provide a mechanism for coordinated modulation of microglial activation, NF-κB signaling, oxidative stress, apoptosis, and tissue repair.

Delivery route represents another major component of therapeutic design.

Intravenous administration is relatively accessible but results in substantial systemic biodistribution. Intrathecal administration provides closer access to the CNS but is more invasive. Intranasal administration offers an attractive strategy for potentially bypassing the BBB, although human evidence remains limited and heterogeneous.

The future of this field is therefore unlikely to be represented by a simplistic model of “stem cells reduce inflammation.”

A more accurate model is:

stem/progenitor cells sense the damaged environment → modulate pathological immune signaling → protect surviving neural cells → release extracellular vesicles and regulatory molecules → stimulate endogenous repair → support remyelination → promote reconstruction of neural homeostasis.

This is the unique attraction of neural stem/progenitor cell therapy.

It is not simply an anti-inflammatory strategy.

It is a potential regenerative immunomodulatory strategy.

The ultimate goal is not the complete elimination of inflammation. It is the transformation of a chronically destructive CNS environment into one that is compatible with resolution, neuroprotection, remyelination, neurogenesis, and functional recovery.

At the same time, scientific enthusiasm must remain proportional to clinical evidence. NSPC transplantation, NSC-derived extracellular vesicles, and miRNA-based regenerative therapies remain areas of active investigation. Major challenges include product standardization, cell-state control, biodistribution, manufacturing, long-term safety, tumorigenicity, optimal delivery, potency assays, and the design of adequately powered randomized clinical trials. Recent reviews of intranasal and EV-based approaches specifically emphasize that promising biological findings have not yet eliminated these translational uncertainties.

The most plausible future therefore lies not in one “miracle” cell, but in a precisely characterized regenerative platform combining neural progenitor biology, immune regulation, extracellular vesicles, microRNA signaling, remyelination, neuroprotection, and rehabilitation.

Such an approach recognizes the central biological reality of neurological disease: the injured nervous system is not damaged by a single mechanism, and consequently its repair is unlikely to be achieved by a single mechanism either.

Selected References and Evidence Base

Neural Stem/Progenitor Cells Regulate Neuroinflammation: Mechanisms and Therapeutic Applications in Neurological Diseases. Recent review emphasizing NSPC–microglia–astrocyte interactions and paracrine immunomodulation.

Regulation of Microglia Function by Neural Stem Cells. Review of NSPC regulation of microglial survival, migration, phagocytosis, and activation.

The Benefits of Neuroinflammation for the Repair of the Injured Central Nervous System. Review explaining why neuroinflammation can be both destructive and regenerative.

Neural Stem/Progenitor Cell-Derived Extracellular Vesicles: A Novel Therapy for Neurological Diseases and Beyond. Review of NSC-EV neuroprotective, neuroregenerative, and immunomodulatory potential.

Neural Stem Cell-Derived Extracellular Vesicles for Advanced Neural Repair. Review addressing neuroinflammation, bioenergetics, mitochondrial transfer, and translational challenges.

Promises and Limitations of Neural Stem Cell Therapies for Progressive Multiple Sclerosis. Discussion of why conventional immunomodulation does not necessarily promote CNS repair in progressive MS.

Progressive Multiple Sclerosis: Evaluating Current Therapies and Exploring Future Treatment Strategies. Recent review emphasizing CNS-compartmentalized inflammation, mitochondrial dysfunction, and neurodegeneration.

Intranasal Administration of Stem Cells and Their Derivatives for Neurological and Respiratory Disorders: A Systematic Review of Human Clinical Trials. 2026 systematic review highlighting feasibility but also small sample sizes, heterogeneity, and risk of bias.

Advances in Clinical Translation of Stem Cell-Based Therapy in Neurological Diseases. Review comparing IV, intrathecal, intracerebral, intra-arterial, and intranasal approaches.

The Safety Profile of Mesenchymal Stem Cell Therapy Administered Through Intrathecal Injections for Treating Neurological Disorders. Systematic review and meta-analysis of randomized trials.

Extracellular Vesicles as Tools and Targets in Therapy for Diseases. Overview of EV biology and therapeutic applications.

Recent Advances in Extracellular Vesicles for Therapeutic Cargo Delivery. Review of EV engineering and cargo-delivery technologies.

Mesenchymal Stem Cell-Derived Extracellular Vesicles Reduce Inflammatory Responses via the miR-146a/NF-κB Pathway. Experimental evidence illustrating how EV-associated miRNA signaling can influence inflammatory pathways.

ClinicalTrials.gov, NCT07467733. Example of a current Phase I/II investigation involving neuroinduced mesenchymal cells and mesenchymal-cell-derived exosomes in spinocerebellar ataxia.

Book Consultation